• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

代谢综合征不会增加亚洲印度人糖耐量受损转化为糖尿病的风险——印度糖尿病预防计划的结果

Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians--Result of Indian diabetes prevention programme.

作者信息

Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V

机构信息

Diabetes Research Centre, M.V. Hospital for Diabetes & WHO Collaborating Centre for Research, Education and Training in Diabetes, 5, Main Road, Royapuram, Chennai 600 013, India.

出版信息

Diabetes Res Clin Pract. 2007 May;76(2):215-8. doi: 10.1016/j.diabres.2006.08.009. Epub 2006 Sep 18.

DOI:10.1016/j.diabres.2006.08.009
PMID:16982107
Abstract

AIMS

In this study, we assessed for the prevalence of metabolic syndrome (MetS) in the cohort of subjects with impaired glucose tolerance (IGT) in the Indian Diabetes Prevention Programme and studied whether the syndrome enhanced the conversion to diabetes.

METHODS

Effectiveness of lifestyle modification (LSM), metformin (Met) and LSM plus Met was tested in a randomised, controlled primary prevention study in subjects with IGT n=502 (M:W 397:105) at a median follow up of 30 months. Baseline prevalence of MetS was calculated using the WHO criteria. Insulin resistance (IR) was calculated using homeostasis model assessment (HOMA) method.

RESULTS

MetS was present in 233 subjects (46.4%; 95% CI 41.9-50.9) in the total group, in men (n=168; 42.3%; 95% CI 37.4-47.3) and in women (n=65; 61.9%; 95% CI 51.9-71.2) (men versus women chi(2)=12.8, p=0.0005). Insulin resistance (HOMA-IR>or=4.1) was present in 69.1% with no gender difference. IR increased proportionately with increasing number of abnormalities, in IGT (39.8%), IGT plus one abnormality (56.5%) and IGT plus any two or more abnormalities (69.1%) (Mantel Haenszel chi(2)=22.8, p<0.0001). Incidence of diabetes was similar in subjects with (40.3%) (n=94/233) or without (40.1%) (n=108/269) MetS (p=0.97). Cox's regression analysis confirmed that MetS did not enhance the conversion rate of IGT to diabetes both in the control (HR=0.88, 95% CI 0.53-1.47, p=0.63) and in the total group (HR=1.02, 95% CI 0.78-1.35, p=0.88), after correcting for effects of intervention.

CONCLUSION

Prevalence of MetS is high in Asian Indian IGT subjects, especially in women. However, it did not influence the rate of conversion of IGT to diabetes.

摘要

目的

在本研究中,我们评估了印度糖尿病预防项目中糖耐量受损(IGT)受试者队列中代谢综合征(MetS)的患病率,并研究该综合征是否会增加糖尿病的转化率。

方法

在一项随机对照的一级预防研究中,对502名IGT受试者(男∶女 = 397∶105)进行了中位随访30个月,测试了生活方式改变(LSM)、二甲双胍(Met)以及LSM加Met的有效性。采用世界卫生组织标准计算MetS的基线患病率。使用稳态模型评估(HOMA)方法计算胰岛素抵抗(IR)。

结果

在全部受试者中,233名受试者(46.4%;95%可信区间41.9 - 50.9)存在MetS,男性(n = 168;42.3%;95%可信区间37.4 - 47.3)和女性(n = 65;61.9%;95%可信区间51.9 - 71.2)中也存在MetS(男性与女性比较,χ² = 12.8,p = 0.0005)。胰岛素抵抗(HOMA-IR≥4.1)的发生率为69.1%,无性别差异。在IGT(39.8%)、IGT加一项异常(56.5%)以及IGT加两项或更多异常(69.1%)中,IR随异常数量增加而呈比例增加(Mantel Haenszel χ² = 22.8,p < 0.0001)。有MetS的受试者(40.3%)(n = 94/233)和无MetS的受试者(40.1%)(n = 108/269)糖尿病发生率相似(p = 0.97)。校正干预效应后,Cox回归分析证实,在对照组(HR = 0.88,95%可信区间0.53 - 1.47,p = 0.63)和全部受试者组(HR = 1.02,95%可信区间0.78 - 1.35,p = 0.88)中,MetS均未增加IGT向糖尿病的转化率。

结论

亚洲印度IGT受试者中MetS患病率较高,尤其是女性。然而,它并未影响IGT向糖尿病的转化率。

相似文献

1
Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians--Result of Indian diabetes prevention programme.代谢综合征不会增加亚洲印度人糖耐量受损转化为糖尿病的风险——印度糖尿病预防计划的结果
Diabetes Res Clin Pract. 2007 May;76(2):215-8. doi: 10.1016/j.diabres.2006.08.009. Epub 2006 Sep 18.
2
Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome--the Chennai Urban Rural Epidemiology Study.糖尿病前期、糖尿病和代谢综合征患者的可溶性P选择素和CD40L水平——金奈城乡流行病学研究
Metabolism. 2006 Feb;55(2):237-42. doi: 10.1016/j.metabol.2005.08.019.
3
Glucose intolerance (diabetes and IGT) in a selected South Indian population with special reference to family history, obesity and lifestyle factors--the Chennai Urban Population Study (CUPS 14).特定南印度人群中的葡萄糖耐量异常(糖尿病和糖耐量受损):特别提及家族史、肥胖和生活方式因素——金奈城市人口研究(CUPS 14)
J Assoc Physicians India. 2003 Aug;51:771-7.
4
Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.吡格列酮与二甲双胍对糖耐量受损和早期糖尿病患者胰岛素抵抗及激素指标影响的比较
Hypertens Res. 2007 Jan;30(1):23-30. doi: 10.1291/hypres.30.23.
5
A diabetes risk score helps identify metabolic syndrome and cardiovascular risk in Indians - the Chennai Urban Rural Epidemiology Study (CURES-38).糖尿病风险评分有助于识别印度人的代谢综合征和心血管风险——金奈城乡流行病学研究(CURES-38)。
Diabetes Obes Metab. 2007 May;9(3):337-43. doi: 10.1111/j.1463-1326.2006.00612.x.
6
Association of leukocyte count with varying degrees of glucose intolerance in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-26).亚洲印度人中白细胞计数与不同程度葡萄糖不耐受的关联:金奈城乡流行病学研究(CURES - 26)
Metab Syndr Relat Disord. 2009 Jun;7(3):205-10. doi: 10.1089/met.2008.0024.
7
Association of physical inactivity with components of metabolic syndrome and coronary artery disease--the Chennai Urban Population Study (CUPS no. 15).身体活动不足与代谢综合征各组分及冠状动脉疾病的关联——金奈城市人口研究(CUPS第15号)
Diabet Med. 2005 Sep;22(9):1206-11. doi: 10.1111/j.1464-5491.2005.01616.x.
8
Lifestyle intervention in individuals with normal versus impaired glucose tolerance.对糖耐量正常与糖耐量受损个体的生活方式干预。
Eur J Clin Invest. 2007 Jul;37(7):535-43. doi: 10.1111/j.1365-2362.2007.01820.x.
9
Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome.印度南部城市非酒精性脂肪性肝病的患病率与不同程度的葡萄糖不耐受和代谢综合征的关系。
Diabetes Res Clin Pract. 2009 Apr;84(1):84-91. doi: 10.1016/j.diabres.2008.11.039. Epub 2009 Jan 24.
10
Comparing the ADA 1997 and the WHO 1999 criteria: Prevalence of Diabetes in India Study.比较美国糖尿病协会1997年标准与世界卫生组织1999年标准:印度糖尿病患病率研究
Diabetes Res Clin Pract. 2004 Dec;66(3):309-15. doi: 10.1016/j.diabres.2004.04.009.

引用本文的文献

1
Incidence and Risk Factors for Progression to Diabetes Mellitus: A Retrospective Cohort Study.进展为糖尿病的发病率和危险因素:一项回顾性队列研究。
Int J Environ Res Public Health. 2021 Dec 23;19(1):123. doi: 10.3390/ijerph19010123.
2
Effectiveness of interventions for the reversal of a metabolic syndrome diagnosis: An update of a meta-analysis of mixed treatment comparison studies.用于逆转代谢综合征诊断的干预措施的有效性:混合治疗比较研究的荟萃分析更新
Biomedica. 2019 Dec 1;39(4):647-662. doi: 10.7705/biomedica.4684.
3
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
二甲双胍用于预防或延缓2型糖尿病高危人群发生2型糖尿病及其相关并发症。
Cochrane Database Syst Rev. 2019 Dec 3;12(12):CD008558. doi: 10.1002/14651858.CD008558.pub2.
4
Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.饮食、体育活动或两者兼用,用于预防或延缓2型糖尿病高危人群发生2型糖尿病及其相关并发症。
Cochrane Database Syst Rev. 2017 Dec 4;12(12):CD003054. doi: 10.1002/14651858.CD003054.pub4.
5
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention.二甲双胍在糖尿病前期和糖尿病预防中的治疗应用。
Drugs. 2015 Jul;75(10):1071-94. doi: 10.1007/s40265-015-0416-8.
6
Testosterone and metabolic syndrome: The link.睾酮与代谢综合征:两者之间的联系。
Indian J Endocrinol Metab. 2012 Mar;16 Suppl 1(Suppl1):S12-9. doi: 10.4103/2230-8210.94248.
7
Treating prediabetes with metformin: systematic review and meta-analysis.使用二甲双胍治疗糖尿病前期:系统评价与荟萃分析。
Can Fam Physician. 2009 Apr;55(4):363-9.
8
Application of cardiovascular disease risk prediction models and the relevance of novel biomarkers to risk stratification in Asian Indians.心血管疾病风险预测模型在亚洲印度人群中的应用以及新型生物标志物与风险分层的相关性。
Vasc Health Risk Manag. 2008;4(1):199-211. doi: 10.2147/vhrm.2008.04.01.199.